

Special Issue

Immune Effectiveness of COVID-19 Vaccines

Message from the Guest Editor

The COVID-19 pandemic has created a global health crisis, with devastating consequences for human lives and economies worldwide. The rapid development of vaccines against COVID-19 has been a crucial step in mitigating the impact of the pandemic. Understanding the immune response to COVID-19 vaccines is crucial to ensure their effectiveness in preventing infection and reducing the spread of the virus, particularly in light of emerging SARS-CoV-2 variants of concern. The knowledge of the immune response to the developed and under-developed vaccines can help to improve vaccine formulation in the future, as well as guide the most effective vaccination programs. This research area has significant implications for public health policy, including vaccine distribution and vaccine hesitancy.

- The immune response to novel COVID-19 under development.
- Populational studies covering the immune response to COVID-19 vaccines.
- Long-term immune response to COVID-19 vaccination.
- Relation between immune response and COVID-19 vaccine effectiveness.
- Breakthrough infections in the COVID-19 vaccinated population.
- Study of cases covering COVID-19 immune response to vaccination and infection.

Guest Editor

Prof. Dr. Luciano Fernandes Huergo
Setor Litoral, Universidade Federal do Parana, Curitiba, Brazil

Deadline for manuscript submissions

closed (30 April 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/167149

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).